Australian Doctor Australian Doctor 17th November 2017 | Page 10

‘‘
‘‘
Dymistaaah
Twice the relief of allergic rhinitis symptoms
compared with an intranasal corticosteroid *1,2
*Compared to fluticasone propionate (FP). Reflective total
7 symptoms score (rT7SS) compared to FP (p = 0.0013) at day
14, post-hoc analysis, placebo subtracted results (n = 610).
PBS Information: This product is not listed on the PBS.
Please review Product Information (PI) before prescribing.
Full PI is available on request by calling 1800 314 527 or at: www.ebs.tga.gov.au
Dymista ® 125/50 (azelastine hydrochloride 125µg /fluticasone proprionate 50µg) nasal spray 17mL, 120 sprays). Indications: Symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children
12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate. Dosage: Adults and adolescents (≥ 12yrs): One spray in each nostril twice daily. Contraindications: Hypersensitivity to the active
substance(s) or excipients. Precautions: Pregnancy (Cat B3) and lactation; operating machinery or driving motor vehicle; use with alcohol or other CNS depressants, somnolence; patients with recent nasal ulcers, surgery or injury to nose
or mouth; patients susceptible to candida infections (e.g. diabetics); glaucoma and/or cataracts; HPA axis effect/suppression, adrenal function impairment; tuberculosis or untreated respiratory infection; children and adolescents (< 12yrs);
severe hepatic and renal impairment. Interactions: Cytochrome P450 CYP3A4 inhibitors (potential increase fluticasone proprionate exposure) eg: ritonavir, ketoconazole, cimetidine; CNS depressants. Adverse Effects: Common: headache,
dysgeusia, unpleasant smell; Uncommon: epistaxis, nasal discomfort, sneezing, nasal dryness, cough, dry throat and irritation; Very rare: somnolence; nasal septal perforation; hypersensitivity including anaphylactic reactions, angioedema
and bronchospasm. Min PI Updated: 05 Jun 2017.
References: 1. Hampel FC et al. Ann Allergy Asthma Immunol 2010;105:168–173. 2. Meltzer E et al. Int Arch Allergy Immunol 2013;16:369–377.
Dymista ® is a registered trademark. MEDA Pharmaceuticals (Aust) Pty Ltd. (A Mylan Company). Level 1, 30–34 Hickson Rd, Millers Point, NSW, 2000, Australia. ABN: 29 601 608 771. Call: 1800 314 527. BB MYL2110A.
DYM-2017-0234. Date of preparation: August 2017.